EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis

Kazuya Okushin, Tomohiro Mitani, Shinya Matsumoto, Ryu Yoneda, Daisuke Ohki, Toshiyuki Kishida, Kazuhiko Ikeuchi, Akira Kado, Ryosuke Tateishi, Mitsuhiro Fujishiro, Tomotaka Yamamoto, Takeya Tsutsumi

Liver International Communications · 2026-06 · 7 (2)

DOI: 10.1002/lci2.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International Communications, online erschienen am 01.06.2026. Verfasst von Kazuya Okushin und 11 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Despite the widespread availability of effective antiviral therapies, progress toward the global elimination of hepatitis C virus (HCV) has been slower than anticipated, highlighting the necessity for more effective screening and confirmation processes. This study quantitatively evaluated the effectiveness of a targeted, timeline‐aware alert system for HCV surveillance in a tertiary‐care hospital.

Methods

This single‐centre observational study evaluated a prospectively implemented diagnostic recommendation system. From June to November 2025, attending physicians received targeted recommendations for HCV RNA testing when patients had positive HCV antibody results, no prior confirmed RNA negativity, and no RNA testing performed ≥ 2 weeks following antibody testing. Outcomes were compared with those of a historical cohort from the corresponding period in 2024. The primary outcome was completion of HCV RNA testing within 90 days of antibody positivity.

Results

During the study period, 13 425 HCV antibody tests were performed, of which 239 (1.8%) tested positive. One hundred eleven patients had no prior history of HCV RNA testing, and alerts were issued to 82 patients who did not undergo HCV RNA testing within 2 weeks. Among them, 34 patients (41.5%) underwent HCV RNA testing within 90 days, which identified five active infections. In contrast, only 10 of 89 patients (11.2%) meeting the same eligibility criteria in the 2024 historical cohort completed RNA testing ( p < 0.001).

Conclusion

Targeted recommendations that account for clinical timelines significantly improve the opportunities for HCV RNA testing in a real‐world hospital setting. Timeline‐aware diagnostic support may help reduce missed diagnostic opportunities and accelerate the progress toward HCV elimination.

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Okushin, K., Mitani, T., Matsumoto, S., Yoneda, R., Ohki, D., Kishida, T., Ikeuchi, K., Kado, A., Tateishi, R., Fujishiro, M., Yamamoto, T., & Tsutsumi, T. (2026). Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis. Liver International Communications, 7(2). https://doi.org/10.1002/lci2.70052

Vancouver

Okushin K, Mitani T, Matsumoto S, Yoneda R, Ohki D, Kishida T, et al. Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis. Liver International Communications. 2026;7(2). doi:10.1002/lci2.70052

BibTeX
@article{Okushin2026,
  author = {Okushin, Kazuya and Mitani, Tomohiro and Matsumoto, Shinya and Yoneda, Ryu and Ohki, Daisuke and Kishida, Toshiyuki and Ikeuchi, Kazuhiko and Kado, Akira and Tateishi, Ryosuke and Fujishiro, Mitsuhiro and Yamamoto, Tomotaka and Tsutsumi, Takeya},
  title = {Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis},
  journal = {Liver International Communications},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/lci2.70052}
}
Kostenlos starten →